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Promoter CpG Island Hypermethylation in Dysplastic
Nevus and Melanoma: CLDN11 as an Epigenetic
Biomarker for Malignancy
Linda Gao1,6, Karin van den Hurk2,6, Peter T.M. Moerkerk2, Jelle J. Goeman3,7, Samuel Beck4,
Nelleke A. Gruis1, Joost J. van den Oord5, Ve´ronique J. Winnepenninckx2,6, Manon van Engeland2,6 and
Remco van Doorn1,6
Dysplastic nevi are melanocytic lesions that represent an intermediate stage between common nevus
and melanoma. Histopathological distinction of dysplastic nevus from melanoma can be challenging and
there is a requirement for molecular diagnostic markers. In this study, we examined promoter CpG island
methylation of a selected panel of genes, identified in a genome-wide methylation screen, across a spectrum
of 405 melanocytic neoplasms. Promoter methylation analysis in common nevi, dysplastic nevi, primary
melanomas, and metastatic melanomas demonstrated progressive epigenetic deregulation. Dysplastic nevi were
affected by promoter methylation of genes that are frequently methylated in melanoma but not in common nevi.
We assessed the diagnostic value of the methylation status of five genes in distinguishing primary melanoma
from dysplastic nevus. In particular, CLDN11 promoter methylation was specific for melanoma, as it occurred in
50% of primary melanomas but in only 3% of dysplastic nevi. A diagnostic algorithm that incorporates
methylation of the CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT genes was validated in an independent
sample set and helped distinguish melanoma from dysplastic nevus (area under the curve 0.81). Melanoma-
specific methylation of these genes supports the utility as epigenetic biomarkers and could point to their
significance in melanoma development.
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INTRODUCTION
Cutaneous melanoma is a malignant tumor that arises from
melanocytes residing in the skin. The lifetime risk of develop-
ing melanoma is approximately 2% in the United States and
Europe and both incidence and mortality rates continue to rise
(Bauer and Garbe, 2003; Ferlay et al., 2010). Early diagnosis
is important to prevent the formation of lethal metastasis.
However, the clinical diagnosis of melanoma is challenging in
a proportion of cases. This applies to visual assessment of
pigmented skin lesions and to histopathological examination
of biopsied tissue, the standard for melanoma diagnosis. A
substantial interobserver discordance rate of 14% in the patho-
logical diagnosis of melanoma has been reported (Brochez
et al., 2002; Shoo et al., 2010). In particular, the sensitivity for
diagnosing early-stage melanomas is low and distinction with
dysplastic melanocytic nevus can be problematic.
Dysplastic nevi are irregular in shape and pigmentation
and occur in approximately 10% of the population (Naeyaert
and Brochez, 2003). Histologically, these lesions demonstrate
random cytological atypia, architectural disorder, and stromal
changes. The relevance of dysplastic nevus to melanoma
progression is underscored by observations that dyplastic
nevi are found in contiguity with melanoma in a significant
subset of cases (Sagebiel, 1993; Weatherhead et al., 2007).
On the basis of morphological and biological characteristics,
dysplastic nevi have been proposed to represent an inter-
mediate lesion between common nevi and malignant
melanoma in the multistep tumor progression model of
melanocytic neoplasia (Elder, 2010).
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In the melanoma progression model proposed by Clark,
melanocytic cells acquire malignant traits in discrete steps,
a process driven by accumulation of genetic and epigenetic
alterations (Clark et al., 1984). Although there is limited
information about genetic and epigenetic alterations in
dysplastic nevi, patterns of intragenic mutations, chromo-
somal aberrations, and DNA methylation alterations are
assumed to differ from those in melanoma. Therefore,
detection of these molecular differences could aid in the
correct classification of those cases in which morphological
diagnosis fails to discriminate.
Systematic characterization of molecular alterations in
melanoma has provided a wealth of information on acquired
DNA alterations in melanoma cells, which could be used in
the molecular diagnosis of this malignant disease. Recently,
we performed a genome-wide promoter methylation analysis
of 14 495 genes in melanoma and common nevus samples
and found widespread aberrant promoter methylation in
melanoma (Gao et al., 2013). Among the hundreds of gene
promoters that exhibited methylation in melanomas but not
in common nevi, we identified several tumor suppressor
genes, causally implicating epigenetic mechanisms in mela-
noma development.
The objectives of this study were to gain insight into
epigenetic deregulation in the different stages of melanocytic
neoplasia and to assess the potential diagnostic value of genes
differentially methylated between melanoma and dysplastic
nevus. To this end, we examined the methylation status
of genes that were previously identified in a genome-wide
methylation screen in a cohort of 251 melanocytic neoplasms
and subsequently validated a diagnostic algorithm incorporat-
ing different gene methylation features in a second indepen-
dent series of 154 dysplastic nevus and primary melanoma
samples. The combined analysis of promoter CpG island
methylation of the five genes proposed in this study could
be of help in the histopathological distinction of melanoma
from dysplastic nevus.
RESULTS
Selection of genes for promoter CpG island methylation analysis
in common nevus, dysplastic nevus, primary melanoma, and
metastatic melanoma
In a previously performed genome-wide methylation analysis
using Infinium 27-k beadchips, we identified 106 genes that
were significantly and frequently more methylated in primary
cutaneous melanomas than in common nevi (Gao et al.,
2013). Here, we set out to analyze the methylation status
of the 12 most differentially methylated genes in dysplastic
nevi, next to an independent set of common nevi and primary
melanomas (Figure 1a and b). Primers for bisulfite melting
curve analysis (BMCA) were designed to encompass or to be
in close proximity of the corresponding 50-mer probe
sequence on the beadchip. C4orf8 and HIST1H3E were
excluded for further methylation analyses owing to suboptimal
primer design; in their place, PPP1R3C and CLDN11 were
included, as we had observed that they exhibited notable
differential methylation between primary melanoma and
common nevus samples (Gao et al., 2013). In the indepen-
dent set of 10 common nevus, 20 dysplastic nevus, and 15
primary melanoma biopsy samples, BMCA showed that
C1orf106, MAPK13, CDH11, GNMT, PPP1R3C, and
CLDN11 methylation was absent in common and dysplastic
nevi, whereas frequent methylation (20–67%) was observed in
primary melanomas (Figure 1c). The promoters of HOXA9 and
CNTN1 were nonprogressively methylated in 10–80% of
common nevi, dysplastic nevi, and primary melanomas.
Interestingly, PLEKHG6 showed progressively higher levels
of methylation with tumor progression, that is, in 0% of
common nevi, 35% of dysplastic nevi, and 60% of primary
melanomas, suggesting that transition from a benign melano-
cytic lesion to a malignant tumor can be accompanied by a
gradual increase in methylation of certain genes (Figure 1c).
LEP showed mosaic methylation in melanoma and nevi, with
only subtle differences between these sample groups, whereas
the ABCA3 promoter region appeared to be unmethylated in
melanoma, as well as in nevi (Supplementary Figure S1
online). Genes showing frequent methylation in melanoma,
but not, or scarcely, in common and dysplastic nevi, were
prioritized for further analyses in a large series of samples.
Differential promoter methylation of CLDN11, CDH11,
PPP1R3C, MAPK13, and GNMT in common nevus, dysplastic
nevus, and melanoma
Promoter methylation of CLDN11, CDH11, PPP1R3C,
MAPK13, and GNMT was assessed in a large series of 251
formalin-fixed, paraffin-embedded (FFPE) biopsy samples con-
sisting of 62 common nevi, 72 dysplastic nevi, 101 primary
melanomas, and 16 melanoma metastases, designated series
1. We applied nested methylation-specific PCR (MSP) because
this method is better suited for analysis of FFPE samples than
BMCA (Derks et al., 2004). To compare the results of BMCA
and MSP, we subjected 31 samples to methylation analysis
using BMCA and MSP. This revealed a high concordance rate
of 84–97% between both techniques, with higher sensitivity
for detecting methylation of MSP (Supplementary Table S1
online). C1orf106 was excluded at this stage owing to sub-
optimal MSP primer design, and methylation analysis by MSP
was performed for CLDN11, CDH11, PPP1R3C, MAPK13,
and GNMT. The characteristics of the five genes are detailed
in Table 1. The promoter CpG island regions of these genes as
Figure 1. Differential promoter methylation of HOXA9, C1orf106,MAPK13, CDH11, EFCAB1, CNTN1, GNMT, PLEKHG6, PPP1R3C, and CLDN11 in common
nevi, dysplastic nevi, and primary melanomas. (a) Schematic depiction of the workflow used to select candidate genes for methylation analyses in large series of
melanocytic biopsy samples. (b) The 12 most frequently methylated genes identified by comparative analysis of genome-wide methylation data from 24 primary
melanomas and five common nevi. (c) Methylation frequency of 10 genes in an independent set of 10 common nevi, 20 dysplastic nevi, and 15 primary
melanomas as assessed by bisulfite melting curve analysis (BMCA). Black triangles indicate the position of the melting curve peak for the respective positive (fully
methylated) and negative (fully unmethylated) control.
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studied by MSP and BMCA are depicted in Figure 2a. MSP
was successfully performed in 87–98% of the samples in series
1 (Figure 2b, Supplementary Table S2 online).
Methylation frequencies of CLDN11, CDH11, PPP1R3C,
MAPK13, and GNMT in common nevi, dysplastic nevi, and
primary and metastatic melanomas are presented in Table 2.
For further analyses and generation of a diagnostic algorithm,
only methylation data of samples for which MSP was
performed successfully for all five genes (55 common nevi,
57 dysplastic nevi, 79 primary melanomas, and 15 metastatic
melanomas) are included in Table 2 and Figure 3. (Results for
all analyzed samples of series 1 are given in Supplementary
Table S3 online.) Remarkably, CLDN11 displayed the
absence of methylation in both common and dysplastic nevi,
whereas it was methylated in 48% of primary melanomas
and 73% of metastatic melanomas in series 1 (Table 2).
CDH11 and PPP1R3C showed the absence of methylation
in common nevi; only 5 and 14% of dysplastic nevi harbored
methylation for CDH11 and PPP1R3C, respectively. Methyla-
tion frequencies in primary and metastatic melanomas were
41 and 47% for CDH11, and 52 and 60% for PPP1R3C,
respectively. GNMT harbored promoter methylation in 4%
of common and 11% of dysplastic nevi, but yet again
higher methylation frequencies were found in primary (46%)
and metastatic (47%) melanomas. For MAPK13, methylation
was observed in 18% of common and 26% of dysplastic
nevi, with higher methylation frequencies in primary (62%)
and metastatic (67%) melanomas. The methylation patterns
of the five genes, showing progressive increase in methylation
frequency in different stages of melanocytic neoplasia, are
depicted in Figure 3a. We noted significantly higher promoter
methylation frequencies in particular following the transi-
tion to melanoma. Methylation of each of the five genes
was detected only 12 times (4%) in 55 common nevi and 32
times (11%) in 57 dysplastic nevi, significantly lower
when compared to 196 times (50%) in 79 primary melanomas
(Po0.001) and 44 times (59%) in 15 metastatic melanomas
(Figure 3b). Complete absence of methylation for all five genes
was found in 44 of 55 (80%) common nevi, 39 of 57 (68%)
dysplastic nevi, 18 of 79 (23%) primary melanomas, and 2 of
15 (13%) metastatic melanomas (Figure 3c). There was no
significant correlation between the grade of atypia of dysplas-
tic nevi and promoter methylation frequency.
Promoter hypermethylation is known to increase with age,
and the mean age of the melanoma patients was higher (63
years) than of the dysplastic nevus patients (46 years). The
differences in methylation frequencies of CLDN11, CDH11,
PPP1R3C, MAPK13, and GNMT between melanomas and
dysplastic nevi were comparable in the subset of patients
younger than 50 years and those older than 50 years
(Supplementary Table S4a online). From this it can be
concluded that the observed methylation differences between
melanoma and dysplastic nevus cannot be attributed to age.
For gender, similar results were obtained (Supplementary
Table S5a online). CLDN11, CDH11, PPP1R3C, MAPK13,
and GNMT promoter methylation has been demonstrated
Table 1. Characteristics of five genes that were selected for methylation analysis in common nevus, dysplastic nevus,
primary melanoma, and metastatic melanoma biopsy samples
Tumor Methylation-associated
Described in
literature as
methylated in:
Gene Function Location suppressor gene silencing Cancer Melanoma
MAPK13 p38 MAP kinase involved in relaying intracellular
signals for a variety of cellular processes
chr6: 36098261–
36112301
Putativea Yesa x x
CDH11 Type II classical cadherin that is an integral
membrane protein mediating calcium-dependent
cell–cell adhesion
chr16: 64980683–
65155919
Establishedb,c,d Yesa x x
GNMT Enzyme that catalyzes the conversion of S-adenosyl-
L-methionine to S-adenosyl-L-homocysteine and
sarcosine
chr6: 42928500–
42931618
Putativee Yesf x x
PPP1R3C Regulatory subunit of protein phosphatase-1 (PP1)
that catalyzes reversible protein phosphorylation
important for a variety of cellular activities
chr10: 93388197–
93392858
Putativeg Yesg x
CLDN11 Claudin family member that is an integral membrane
protein and component of tight-junction strands
chr3: 170136653–
170152479
Putativea Yesh x x
aGao et al., 2013.
bListed in the Cancer Gene Census (http://cancer.sanger.ac.uk/cancergenome/projects/census/).
cLi et al., Oncogene, 2012.
dMarchong et al., 2010.
eDebRoy et al., 2013.
fHuidobro et al., 2013.
gBonazzi et al., 2009.
hAgarwal et al., 2009.
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to be associated with transcriptional silencing in tumor cell
lines (Table 1). Additional pathway analysis specified that the
products of these five genes and their predicted interactors are
part of gene signaling networks involved in cell–cell adhesion,
cell junction assembly, and adherens junction organization
(Supplementary Figure S2 online).
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Figure 2. Methylation analysis of CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT in large series of common nevi, dysplastic nevi, primary and
metastatic melanomas. (a) CpG island promoter region of the five genes, with the location of the primers used for methylation-specific PCR (MSP) and
bisulfite melting curve analysis (BMCA) in this study. (b) Electrophoretic analysis of MSP amplification products of CLDN11, CDH11, PPP1R3C, MAPK13,
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Table 2. Methylation frequency of five candidate genes in biopsy samples of series 1 (55 common nevi, 57 dysplastic
nevi, 79 primary melanomas, and 15 metastatic melanomas), together with the specificity and sensitivity of each
gene for the distinction of primary melanoma samples from dysplastic nevus samples of series 1
Common nevus Dysplastic nevus Primary melanoma Metastatic melanoma
Dysplastic nevus (n¼ 57),
primary melanoma (n¼ 79)
Methylation frequency
Specificity Sensitivity
No. of samples No. of samples No. of samples No. of samples
CLDN11 0% 0/55 0% 0/57 48% 38/79 73% 11/15 100% 48%
CDH11 0% 0/55 5% 3/57 41% 32/79 47% 7/15 95% 41%
PPP1R3C 0% 0/55 14% 8/57 52% 41/79 60% 9/15 86% 52%
MAPK13 18% 10/55 26% 15/57 62% 49/79 67% 10/15 74% 62%
GNMT 4% 2/55 11% 6/57 46% 36/79 47% 7/15 89% 46%
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A diagnostic algorithm combining epigenetic markers to
distinguish melanoma and dysplastic nevus
The diagnostic specificities and sensitivities of CLDN11,
CDH11, PPP1R3C, MAPK13, and GNMT for the distinction
of primary melanomas from dysplastic nevi of series 1 are
given in Table 2. After having determined these characteristics
of the five methylation markers individually, we continued by
examining which combinations of markers could aid in the
differential diagnosis of primary melanoma and dysplastic
nevus. Diagnostic algorithms were created using the set of 57
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dysplastic nevi and 79 primary melanomas from series 1, and
the accuracy of these models was subsequently tested in
a second sample set consisting of 72 dysplastic nevus and
82 primary melanoma biopsy samples, designated series 2.
In series 1, the three most differentially methylated genes were
CLDN11, CDH11, and PPP1R3C. A first, simple three-gene
diagnostic model was created that considers methylation
of either of these three genes as indicative of melanoma.
This model yielded a specificity of 89% and sensitivity of 67%
in series 2 used as test set (Figure 4a).
As CLDN11 methylation occurred exclusively in melanoma
in series 1 used as training set, this epigenetic event had the
highest discriminatory value with a specificity of 100% and
sensitivity of 48% (Table 2). On the basis of a logistic regres-
sion model, a diagnostic algorithm was constructed consisting
of two discrete steps. First, CLDN11 methylation was eval-
uated, and, if present, a lesion was classified as melanoma.
Second, methylation of CDH11, PPP1R3C, MAPK13, and
GNMT was taken in consideration for samples with no
CLDN11 methylation (Figure 4a). Adding methylation
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information of the other four genes generated additional
diagnostic value by increasing the sensitivity of the model
to detect melanoma. This model has a receiver operating
characteristic curve with an area under the curve of 0.806
(Figure 4b). The condition that a lesion is classified as
melanoma if CLDN11 or at least two other genes are
methylated yields a specificity of 89% and sensitivity of
66% in series 2 (Figure 4a). Promoter methylation frequencies
and patterns of the five interrogated genes in series 2,
visualized in Figure 4c and d and reported in Supple-
mentary Table S6a online, were generally similar
to that of series 1. In series 2, CLDN11 methylation was
detected in 6% of dysplastic nevus samples and 52%
of primary melanoma samples. Validation of methyl-
ation frequencies for the five genes in sample series 2
demonstrated that, in addition to CLDN11, also methylation
of CDH11, PPP1R3C, and GNMT have high specificity for
melanoma.
DISCUSSION
Dysplastic nevi are melanocytic neoplasms with cytonuclear
and architectural atypia and stromal alterations and are
generally considered to constitute an intermediate stage
between common nevi and melanoma. These lesions have
an increased risk of developing into melanoma, and it can be
difficult to clinically distinguish dysplastic nevus from early-
stage melanoma (Naeyaert and Brochez, 2003). In this study,
we examined promoter CpG island methylation of 12 genes,
previously identified in a genome-wide methylation screen, in
metastatic and primary melanoma, dysplastic nevus, and
common nevus biopsy specimens. We observed progressive
promoter CpG island hypermethylation of these genes, with
the methylation frequencies increasing from common nevus
to metastatic melanoma. Dysplastic nevi, although less
commonly than melanoma, demonstrate promoter hyper-
methylation of genes with tumor-suppressive functions, inclu-
ding CDH11. This shows that dysplastic nevi may already
resemble their malignant counterparts at the epigenetic level
and suggests that epigenetic instability can occur early, in
premalignant stages of melanocytic neoplasia. In addition, it
reinforces the notion of dysplastic nevus as an intermediate
step in melanoma progression.
Promoter CpG island methylation analysis in a first, smaller
series of samples using BMCA suggested that promoters of
the CLDN11, CDH11, PPP1R3C, MAPK13, and GNMT genes
could be selectively methylated in melanoma. This would
render these methylation events suitable epigenetic bio-
markers to improve the diagnosis of melanoma and to allow
distinction with dysplastic nevus. Using MSP in a large series
of 251 melanocytic neoplasm samples, we were able to show
the discriminatory value of detecting promoter methylation of
these five genes. Methylation detection by the MSP technique
is especially suited in this setting, as it yields reproducible
results and can directly be applied to FFPE-based samples in
the clinic. On the basis of a logistic regression model analysis,
we developed a diagnostic score that incorporates different
gene methylation features, consisting of assessment of
CLDN11 methylation first, followed by determination of the
methylation frequency of CDH11, PPP1R3C, MAPK13, and
GNMT in DNA isolated from a biopsy sample. Testing of the
diagnostic accuracy of this score in another independent series
consisting of 82 primary melanoma and 72 dysplastic nevus
samples revealed a receiver operating characteristic area
under the curve of 0.806 in this independent test set. A
simpler three-gene model that incorporates only CLDN11,
CDH11, and PPP1R3C as marker of melanoma has a
specificity of 89% and sensitivity of 67% in the validation
sample set. In our analysis, we have pursued methylation
events that are present in melanoma and do not occur in
dysplastic nevus. This has resulted in a panel of epigenetic
markers with very high specificity for melanoma, but with
moderate sensitivity. In particular for screening purposes, a
sensitive test would be preferred over a more specific test. By
varying the parameters of the logistic regression model or
addition of genes that are more frequently methylated in
melanoma, such as HOXA9, an increase in sensitivity can be
achieved, but at the expense of specificity. The binary results
of methylation detection may confer an advantage over
comparative genomic hybridization, fluorescent in situ hybri-
dization, or combined immunohistochemical detection of
melanoma markers, where interpretation of results can have
higher interobserver variability (Gerami et al., 2009; Kashani-
Sabet et al., 2009; Zhang and Li, 2012). Comparative genomic
hybridization and fluorescent in situ hybridization, genomic
methodologies used primarily in the research setting, may
yield higher diagnostic accuracy than methylation detection
of a few genes.
Remarkably, methylation of the CLDN11 gene was com-
pletely specific for melanoma, that is, methylation affected
48% of primary melanoma and 73% of metastatic samples,
whereas it was absent in common and dysplastic nevi in the
first large sample series. In the second sample series, used to
validate the diagnostic algorithm, CLDN11 was found to be
methylated in 6% of dysplastic nevus samples. Detection of
CLDN11 methylation might in particular be used clinically to
distinguish malignant from benign melanocytic lesions. Its
methylation was shown previously to be associated with trans-
criptional silencing (Agarwal et al., 2009). CLDN11 encodes a
member of the claudin family, components of tight junctions
that maintain a physical barrier and polarity of cells. CLDN11
hypermethylation was previously reported in bladder and
gastric cancer, where epigenetic silencing increased cell
motility and invasiveness (Agarwal et al., 2009; Awsare
et al., 2011). Interestingly, in mouse skin tumorigenesis,
changes were found in the distribution pattern of claudin
tight-junction proteins, where epidermal expression of claudin
proteins including Cldn11 decreased during tumor progression
(Arabzadeh et al., 2007). We hypothesize that in melanoma
development loss of CLDN11 expression through promoter
hypermethylation facilitates invasive behavior by disrupting
intercellular cohesion provided by tight-junction structures.
In addition, methylation of CDH11, PPP1R3C, and GNMT
occurred in more than half of melanomas but rarely in
dysplastic nevi. The results for CDH11 are in line with
previous studies showing that methylation of this cadherin
gene that inhibits tumor growth and metastasis preferentially
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occurs in lymph node metastases of melanoma patients
(Carmona et al., 2012). Tumor-suppressive properties have
also been reported for PPP1R3C and GNMT.
Thus far, promoter methylation studies in melanoma often
used a limited number of clinical specimens and lacked
examination of non-malignant samples, thereby making it
impossible to distinguish cancer-specific from tissue-specific
methylation events (van den Hurk et al., 2012). Only few
studies analyzed promoter methylation in dysplastic nevi, and
most of them examined single candidate genes in small
sample sets (Sharma, 2006; Conway et al., 2011; Helmbold
et al., 2012). To our knowledge, this is a previously unreported
study that makes use of a large series of clinical specimens to
show that promoter methylation of several genes, including
tumor suppressor genes, is present to a small extent in
dysplastic nevi. Using the methylation pattern of five genes,
we propose a diagnostic algorithm to distinguish melanoma
from benign melanocytic lesions. The presence of CLDN11,
CDH11, PPP1R3C, and GNMT methylation in a suspicious
melanocytic lesion might be regarded as an indicator of
malignancy. Taken together, the findings presented in this
study provide insight in the epigenetic changes that occur in
melanoma development and can aid in the molecular
diagnosis of melanocytic lesions.
MATERIALS AND METHODS
Patient samples
To prioritize the 12 candidate genes, we analyzed an independent
set of fresh-frozen or boonfix-fixed, paraffin-embedded (BFPE)
tissues from patients diagnosed with common nevus (n¼ 10), dys-
plastic nevus (n¼ 20), and primary melanoma (n¼ 15) at Leiden
University Medical Center (LUMC), the Netherlands. For confirmation
of methylation frequencies and testing of diagnostic discrimi-
natory value of the final five genes, we examined FFPE tissues from
patients diagnosed with common nevus (n¼ 62), dysplastic nevus
(n¼ 72), primary melanoma (n¼ 101), and metastatic melanoma
(n¼ 16) at the Maastricht University Medical Center (MUMC), the
Netherlands, and University Hospitals of the University of Leuven
(KUL), Belgium (series 1). For validation of the diagnostic algorithm,
we examined fresh-frozen, BFPE, and FFPE tissues from patients
diagnosed with dysplastic nevus (n¼ 74) and primary melanoma
(n¼ 82) at LUMC, MUMC, and KUL (series 2). The grade of
atypia (mild and moderate-severe) of dysplastic nevi was determined
by an experienced dermatopathologist (VJW), based on criteria
formulated by Arumi-Uria et al., 2003. Detailed clinicopathological
information of all samples is listed in Supplementary Table S7 online.
Tissues were processed as previously described (Winnepenninckx
et al., 2006); biopsy samples contained at least 50% melano-
cytic cells, as analyzed on hematoxylin and eosin-stained sections.
Patient consent for experiments was not required because French
laws consider human tissue left over from surgery as discarded
material.
DNA isolation and bisulfite conversion
Genomic DNA from fresh-frozen and BFPE tissues was extracted with
the Genomic-tip kit (Qiagen, Venlo, The Netherlands) and the
RecoverAll Nucleic Acid kit (Ambion, Carlsbad, CA), respectively;
DNA from FFPE tissues was extracted by macrodissection with the
QIAamp DNA Micro Kit (Qiagen) or with the Maxwell 16 FFPE Plus
LEV DNA Purification kit (Promega, Leiden, The Netherlands).
Bisulfite conversion was performed using either the EZ DNA
methylation kit (Zymo Research, Orange, CA; BMCA) or the EpiTect
Bisulfite Kit (Qiagen; MSP analysis).
Bisulfite melting curve analysis
Bisulfite primers were designed, and the sensitivity of primer sets
was tested as previously described (Gao et al., 2013; Supplementary
Table S8 online). Methylation could be accurately detected if 10% of
the analyzed DNA was methylated. Melting curves were generated
for each biopsy sample; a sample was considered methylated if the
amplicon had at least 10% methylated DNA, with the melting curve
pattern of a 1:9 methylated to unmethylated DNA mixture serving as
scoring standard.
Methylation-specific PCR
MSP analysis using MSP primers on bisulfite-treated DNA was
performed as described (Herman et al., 1996; Derks et al., 2004;
Supplementary Table S8 online). To facilitate MSP analysis on DNA
retrieved from FFPE tissue, DNA was first amplified with flanking PCR
primers used as template for the PCR. All PCRs were performed with
controls for unmethylated alleles (DNA from human umbilical vein
endothelial cells, methylated alleles (normal lymphocyte DNA treated
in vitro with Sssl methyltransferase (IVD)), and a control without
DNA. To ensure reproducibility, MSP reactions have been performed
in duplicate or triplicate starting from DNA amplification with
flanking PCR primers. The reproducibility was 493% for all primer
sets. Nonconcordant MSP results were analyzed a third time, and two
out of three concordance was used as the end result. Bands with
approximately equal intensity for unmethylated and methylated DNA
were scored as positive for methylation. Faint methylated bands were
considered negative for methylation. Unclear results were analyzed a
second time. In most cases, methylation levels were clearly negative
(no M-band detected) or positive (strong M-band detected).
Statistical analysis
Fisher’s exact test was applied to measure the association between
two sample groups within a 2 2 contingency table; a two-sided P-
value o0.05 was considered significant. Logistic regression analysis
was used to test the diagnostic value of the five genes in the training
data set. The logistic regression did not converge because of the
strong diagnostic effect of CLDN11; therefore, we opted for a two-
step model: data were filtered for samples without CLDN11 methyla-
tion, followed by binary logistic regression analysis with a single
covariate counting how many of CDH11, PPP1R3C, MAPK13, and
GNMT were methylated. In the resulting diagnostic score, a patient
sample was classified as melanoma if either CLDN11 was methylated
or if at least 1, 2, 3, or 4 of CDH11, PPP1R3C, MAPK13, and GNMT
were methylated, depending on the chosen cutoff. A receiver
operating characteristic curve was plotted for this diagnostic score.
For this assessment, an independent test set was used in order to
prevent any optimism bias due to overfit. Statistical analyses were
performed using SPSS 20 (IBM, Armonk, NY) and R (R Core Team
(2013)—http://R-project.org/).
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